This trial is testing a new drug, MK-1084, on patients with solid tumors that have a specific mutation. The trial will also test MK-1084 in combination with another drug, pembrolizumab, on patients with lung cancer who have the same mutation.
3 Primary · 4 Secondary · Reporting Duration: Up to ~50 months
264 Total Participants · 2 Treatment Groups
Primary Treatment: MK-1084 · No Placebo Group · Phase 1
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: